BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives $15.57 Consensus Target Price from Analysts

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) have been given an average rating of “Moderate Buy” by the seven analysts that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $15.57.

BCRX has been the subject of a number of research analyst reports. Royal Bank of Canada restated an “outperform” rating and set a $11.00 price objective (up from $10.00) on shares of BioCryst Pharmaceuticals in a report on Tuesday, February 25th. Wedbush initiated coverage on BioCryst Pharmaceuticals in a report on Tuesday, February 25th. They set an “outperform” rating and a $15.00 price objective for the company. HC Wainwright restated a “buy” rating and set a $30.00 price objective on shares of BioCryst Pharmaceuticals in a report on Tuesday, February 25th. JMP Securities reiterated a “market outperform” rating and issued a $18.00 price target on shares of BioCryst Pharmaceuticals in a report on Friday, January 31st. Finally, Needham & Company LLC increased their price target on BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a “buy” rating in a report on Monday, January 13th.

BioCryst Pharmaceuticals Stock Down 1.3 %

Shares of BioCryst Pharmaceuticals stock opened at $7.64 on Friday. BioCryst Pharmaceuticals has a fifty-two week low of $4.03 and a fifty-two week high of $9.50. The firm has a market cap of $1.60 billion, a PE ratio of -12.52 and a beta of 1.85. The business’s fifty day moving average is $8.13 and its two-hundred day moving average is $7.84.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings data on Monday, February 24th. The biotechnology company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.06). The firm had revenue of $131.50 million during the quarter, compared to analyst estimates of $126.64 million. The firm’s revenue was up 40.8% on a year-over-year basis. During the same period last year, the firm posted $0.28 EPS. Equities research analysts anticipate that BioCryst Pharmaceuticals will post -0.36 EPS for the current year.

Institutional Trading of BioCryst Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the stock. California State Teachers Retirement System boosted its position in BioCryst Pharmaceuticals by 4.1% in the 4th quarter. California State Teachers Retirement System now owns 184,485 shares of the biotechnology company’s stock valued at $1,387,000 after buying an additional 7,232 shares during the last quarter. Mackenzie Financial Corp boosted its position in BioCryst Pharmaceuticals by 190.7% in the 4th quarter. Mackenzie Financial Corp now owns 84,662 shares of the biotechnology company’s stock valued at $637,000 after buying an additional 55,535 shares during the last quarter. GF Fund Management CO. LTD. purchased a new position in BioCryst Pharmaceuticals in the 4th quarter valued at about $33,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in BioCryst Pharmaceuticals by 3.0% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 401,111 shares of the biotechnology company’s stock valued at $3,016,000 after buying an additional 11,581 shares during the last quarter. Finally, Woodline Partners LP purchased a new position in BioCryst Pharmaceuticals in the 4th quarter valued at about $3,385,000. 85.88% of the stock is currently owned by institutional investors and hedge funds.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.